Myocardial protection of esmolol in patients undergoing cardiopulmonary bypass valve replacement

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045578

Enrollment

Unknown

Registered

2021-04-19

Start date

2021-05-10

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Valvular heart disease

Interventions

placebo group:Do not use esmolol

Pretreatment group of esmolol:500 µg/kg.Bolus +100 µg/kg/min from the beginning of dermectomy to aorta occlusion

Aftertreatment group of esmolol:The aorta was opened until heparin was neutralized, 500 µg/kg. Bolus +100 µg/kg/min

the whole processing treatment with esmolol:skin incision until heparin is neutralized, 500 µg/kg. Bolus +100 µg/kg/min

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults (30-65 years old, BMI:18-25kg/m2) were to undergo valve replacement under cardiopulmonary bypass.

Exclusion criteria

Exclusion criteria: 1. Bradycardia (HR = IV; emergency surgery; 5. Active stage of rheumatic diseases; serious systemic diseases, including lung diseases, liver, kidney, musculoskeletal diseases or immune system diseases; cases of asthma and history of blocker allergy; taking hypoglycemic drugs or tea Alkali patients.

Design outcomes

Primary

Measure	Time frame
Troponin protein I;Cardiac ejection fraction;Index of the heart;Cardiac output;	—

Secondary

Measure	Time frame
ICU stay time;length of stays;	—

Countries

China

Contacts

Public ContactLiu Bi

Kunming Yan'an Hospital

13619679193@163.com+86 13619679193

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026